Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Status:
Terminated
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Primary
Compare response rates (relative change in tumor size) to induction chemotherapy consisting
of cisplatin/paclitaxel/cetuximab +/- everolimus.
Secondary:
Determine the maximum administered dose (MAD), maximum tolerated dose (MTD), dose limiting
toxicity (DLT), and safety of everolimus with cisplatin/paclitaxel/cetuximab induction
chemotherapy (phase I portion)